Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

US Patent 8551977 · Granted Oct 8, 2013

Estimated economic value: $655,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of assessing growth hormone deficiency in humans by a macimorelin contain2019
LHRH—antagonists in the treatment of fertility disorders2015
Application of initial doses of LHRH analogues and maintenance doses of LHRH ant2014
Use of perifosine in combination with antimetabolites for the treatment of benig2013
Use of perifosine in combination with antimetabolites for the treatment of benig2013
Use of perifosine in combination with antimetabolites for the treatment of benig2013
Use of alkylphosphocholines in combination with antitumor medications for the tr2013
Use of alkylphosphocholines in combination with antitumor medications for the tr2013
Use of alkylphosphocholines in combination with antitumor medications for the tr2013
Use of alkylphosphocholines in combination with antimetabolites for the treatmen2013
Use of alkylphosphocholines in combination with antimetabolites for the treatmen2013
Use of alkylphosphocholines in combination with antimetabolites for the treatmen2013